 |
|
|
|
February 2007 Cover
|
|
Up to 95 percent of patients treated with the fusion inhibitor Fuzeon in combination with an antiretroviral can achieve undetectable HIV levels, Swiss drug maker Roche said recently.
Without Fuzeon, 60 to 70 percent of patients achieved undetectable HIV levels taking Merck's MK-0518, an integrase inhibitor designed to block the reproduction of HIV, Roche said.
The results were based on a 24-week Phase II study of MK-0518 in treatment-experienced patients with resistance to protease inhibitors. "Such response rates have never been
achieved in clinical trials of HIV patients living with drug-resistant virus," Roche said.
from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
